CalciMedica, Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter report. The filing was signed March 28, 2024.
Business context
CalciMedica is a clinical-stage biopharmaceutical company developing CRAC channel inhibitors. Its lead candidate, intravenous Auxora (zegocractin), is being studied for acute pancreatitis (AP), asparaginase-induced pancreatic toxicity (AIPT) and acute kidney injury (AKI). The company has no approved products and has never generated product-sales revenue.
On March 20, 2023, the company completed its merger with Graybug Vision and adopted the CalciMedica name. The transaction was accounted for as a reverse recapitalization, with Private CalciMedica as accounting acquirer. Accordingly, 2023 financial statements include Graybug’s activity only from March 21, 2023, while 2022 results are for Private CalciMedica alone; comparisons are therefore affected by the transaction and are not fully like-for-like.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $15.9 million | $8.4 million |
| General and administrative expense | $22.2 million | $5.8 million |
| Total operating expenses | $38.1 million | $14.2 million |
| Operating loss | $38.1 million | $14.2 million |
| Other income, net | $3.7 million | $6.4 million |
| Net loss | $34.4 million | $7.8 million |
| Cash used in operating activities | $25.7 million | $11.8 million |
- At December 31, 2023, cash and cash equivalents were $5.5 million and short-term investments were $5.7 million, totaling approximately $11.2 million. Current assets were $11.6 million and current liabilities were $4.0 million.
- Total liabilities were $4.0 million at year-end; the convertible promissory notes and warrant liabilities outstanding at December 31, 2022 were converted or reclassified in connection with the merger. The filing reports no long-term liabilities at December 31, 2023.
- Financing activities provided $20.9 million in 2023, including $14.9 million of net cash acquired in the merger and $10.3 million from a private placement, partly offset by $4.5 million of merger transaction costs. Investing activities provided $8.9 million, principally from investment maturities.
- Management said the year-end resources plus the January–February 2024 private placement proceeds were expected to fund operations into the second half of 2025 and specified clinical milestones through the first half of 2025. Management also said this funding would not carry candidates through regulatory approval or fund certain additional programs.
- The 2024 private placement raised $20.4 million gross and approximately $19.0 million net. It included common shares and warrants, creating potential dilution. At December 31, 2023, $99.7 million remained available under the shelf registration statement and $4.4 million under the ATM facility.
Profit margins are not meaningful because the company reported no product revenue. FY2023 net loss per share was $7.66 versus $111.16 in FY2022; the substantially different weighted-average share counts and merger-related recapitalization make per-share comparison difficult.
Material changes and unusual items
- Operating expenses increased $23.9 million year over year. R&D expense rose 90%, mainly from higher personnel and clinical-development costs; G&A rose 280%, largely from merger-related and public-company costs.
- FY2023 expenses included $16.2 million of one-time merger-related charges: $10.5 million for accelerated vesting of Graybug stock awards and $5.7 million for severance.
- Other income declined from $6.4 million to $3.7 million, principally because gains from fair-value changes in convertible notes and warrants were lower. These non-cash valuation items contributed to reported earnings and should be distinguished from operating performance.
- FY2023 stock-based compensation was $12.0 million, including the $10.5 million acceleration charge. The company’s accumulated deficit was $146.1 million.
Pipeline, outlook and risks
- AP: The Phase 2b CARPO trial was ongoing, with topline results expected in the second quarter of 2024; assuming positive results, management planned to start Phase 3 in 2025. A significant portion of enrollment was expected in India, and the company cautioned that regulators may not accept foreign-trial data.
- AIPT: The first nine-patient cohort of the investigator-sponsored CRSPA trial was completed. Reported comparisons with historical controls suggested shorter hospitalization and less need for ICU care and parenteral nutrition, but the cohort was small and not a randomized controlled comparison. Further data were expected in 2025.
- AKI: The FDA cleared the KOURAGE Phase 2 trial IND in February 2024. The planned 150-patient trial was expected to begin in the second quarter of 2024, with data expected in 2025.
- COVID-19: In the Phase 2 CARDEA trial, Auxora was associated with 30-day mortality of 7.7% versus 17.6% with placebo (reported p=0.0165 in the principal efficacy analysis). At 60 days, mortality was 13.8% versus 20.6% (p=0.1449); median recovery time was seven versus ten days (p=0.098). The company said it would not pursue further development for COVID-19 pneumonia, though a mechanically ventilated-patient study could inform broader respiratory-failure work.
- Other candidates: CM6336 was undergoing IND-enabling preclinical testing, with IND submissions planned for chronic pancreatitis and rheumatoid arthritis in 2025, subject to funding. Other proposed indications are supported by preclinical findings, not established clinical efficacy.
- Management expects continued losses and rising R&D and G&A spending. The company will need substantial additional funding; future financing may be unavailable or dilutive, or require restrictive terms or licensing rights. It cautioned that its cash-runway estimates rely on assumptions and could change.
- Key risks include clinical-trial failure or delay, patient enrollment, acceptance of India trial data, reliance on third-party manufacturers and CROs, a single-source supplier in China, regulatory uncertainty, intellectual-property protection, competition, reimbursement and the ability to raise capital. The company has no commercial infrastructure.
- The company reported no currently pending litigation it believed could have a material adverse effect. The independent auditor issued an unqualified opinion on the financial statements; it did not audit internal control over financial reporting. Management concluded disclosure controls were effective at a reasonable assurance level.
Most important facts for investors to verify
- Whether CARPO results support the planned Phase 3 trial, including trial endpoints, dose response, safety, and the impact and regulatory acceptability of enrollment in India.
- Whether the cash-runway estimate remains realistic after actual spending, trial costs, and the 2024 private placement; also assess the timing and terms of future financing needs.
- The dilution from the 2024 placement warrants and any future use of the ATM or shelf registration, alongside the company’s current share count.
- Whether the promising AIPT findings are confirmed as CRSPA enrolls additional patients, recognizing the initial historical-control comparison’s limitations.
- Whether KOURAGE starts and enrolls on schedule and whether its results support Auxora’s proposed AKI benefit.
- How much of the reported loss reflects recurring operating costs versus merger-related charges, stock compensation, and fair-value gains on financial instruments.